Royal Bank of Canada Trims Position in GE HealthCare Technologies Inc. $GEHC

Royal Bank of Canada decreased its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,451,507 shares of the company’s stock after selling 42,657 shares during the quarter. Royal Bank of Canada’s holdings in GE HealthCare Technologies were worth $103,319,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Empowered Funds LLC grew its stake in shares of GE HealthCare Technologies by 6.1% during the 1st quarter. Empowered Funds LLC now owns 28,848 shares of the company’s stock valued at $2,328,000 after purchasing an additional 1,665 shares during the period. Acadian Asset Management LLC bought a new position in shares of GE HealthCare Technologies in the 1st quarter worth approximately $259,000. Cresset Asset Management LLC lifted its stake in shares of GE HealthCare Technologies by 12.5% in the 2nd quarter. Cresset Asset Management LLC now owns 7,802 shares of the company’s stock worth $578,000 after purchasing an additional 865 shares during the period. Jump Financial LLC boosted its holdings in shares of GE HealthCare Technologies by 317.6% in the second quarter. Jump Financial LLC now owns 28,132 shares of the company’s stock worth $2,084,000 after buying an additional 21,396 shares during the last quarter. Finally, Gamco Investors INC. ET AL boosted its holdings in shares of GE HealthCare Technologies by 8.6% in the second quarter. Gamco Investors INC. ET AL now owns 4,041 shares of the company’s stock worth $299,000 after buying an additional 320 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Down 2.7%

GEHC stock opened at $68.02 on Friday. The business’s 50-day moving average price is $64.02 and its 200-day moving average price is $70.55. The stock has a market cap of $30.94 billion, a P/E ratio of 15.60, a PEG ratio of 1.90 and a beta of 0.72. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 0.92. GE HealthCare Technologies Inc. has a twelve month low of $58.75 and a twelve month high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.26 billion. During the same period in the prior year, the firm posted $1.06 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Friday, July 24th will be given a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, July 24th. GE HealthCare Technologies’s dividend payout ratio is presently 3.21%.

GE HealthCare Technologies News Summary

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
• Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
• Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
• Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GEHC. Hovde Group began coverage on shares of GE HealthCare Technologies in a research report on Friday, July 17th. They set a “market perform” rating and a $14.00 target price for the company. Evercore reiterated an “outperform” rating and issued a $84.00 price target on shares of GE HealthCare Technologies in a research report on Thursday. Wells Fargo & Company lifted their price target on shares of GE HealthCare Technologies from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday. Mizuho cut their price objective on shares of GE HealthCare Technologies from $90.00 to $80.00 in a research report on Thursday, April 30th. Finally, BNP Paribas Exane reduced their price objective on GE HealthCare Technologies from $95.00 to $88.00 in a research note on Friday, May 1st. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Hold” and an average target price of $77.73.

Insider Transactions at GE HealthCare Technologies

In other news, Director Rodney F. Hochman bought 1,618 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were bought at an average price of $62.03 per share, for a total transaction of $100,364.54. Following the purchase, the director owned 1,618 shares in the company, valued at $100,364.54. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Watkin Phoebe L. Yang bought 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average cost of $63.01 per share, with a total value of $63,010.00. Following the acquisition, the director directly owned 13,702 shares in the company, valued at $863,363.02. This trade represents a 7.87% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 12,618 shares of company stock valued at $805,175 over the last three months. Corporate insiders own 0.36% of the company’s stock.

GE HealthCare Technologies Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.